BlackRock Inc. Takes Position in Prestige Consumer Healthcare Inc. $PBH

BlackRock Inc. purchased a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 2nd quarter, Holdings Channel reports. The fund purchased 7,831,333 shares of the company’s stock, valued at approximately $370,187,000. BlackRock Inc. owned approximately 0.17% of Prestige Consumer Healthcare as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of PBH. Leeward Investments LLC MA boosted its holdings in shares of Prestige Consumer Healthcare by 23.3% during the fourth quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock worth $23,894,000 after purchasing an additional 73,162 shares during the period. Legato Capital Management LLC increased its stake in Prestige Consumer Healthcare by 532.4% in the 4th quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock valued at $1,713,000 after buying an additional 23,382 shares during the period. Brandes Investment Partners LP increased its stake in Prestige Consumer Healthcare by 93.2% in the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after buying an additional 292,744 shares during the period. Bessemer Group Inc. lifted its position in Prestige Consumer Healthcare by 20.9% in the 1st quarter. Bessemer Group Inc. now owns 374,691 shares of the company’s stock worth $22,207,000 after buying an additional 64,760 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in shares of Prestige Consumer Healthcare by 68.3% during the 4th quarter. Royce & Associates LP now owns 97,750 shares of the company’s stock valued at $6,030,000 after buying an additional 39,685 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

PBH stock opened at $51.38 on Wednesday. The firm has a 50 day moving average of $49.90 and a two-hundred day moving average of $54.84. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $71.07. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of 14.39, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The business had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. Prestige Consumer Healthcare’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PBH shares. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).